Md Abdus Subhan

Dr. Md Abdus Subhan

https://www.sust.edu/d/che/faculty-profile-detail/81
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Md Abdus SubhanMd Abdus Subhan
Md Abdus Subhan
KYKishan Yalamarty
Kishan Yalamarty
Nina FilipczakNina Filipczak
Nina Filipczak
FPfarzana parveen
farzana parveen
VTVladimir P. Torchilin
Vladimir P. Torchilin
Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.

12 May 2015 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
SWSimon Wanninger
Simon Wanninger
VLVolker Lorenz
Volker Lorenz
Md Abdus SubhanMd Abdus Subhan
Md Abdus Subhan
FEFrank Thomas Edelmann
Frank Thomas Edelmann
This Tutorial Review provides the first general overview on synthesis and medicinal applications of metal curcumin complexes, including anticancer activity and anti-Alzheimer's disease activity.

1 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KYKishan Yalamarty
Kishan Yalamarty
Nina FilipczakNina Filipczak
Nina Filipczak
XLXiang Li
Xiang Li
Md Abdus SubhanMd Abdus Subhan
Md Abdus Subhan
FPfarzana parveen
farzana parveen
VTVladimir P. Torchilin
Vladimir P. Torchilin
Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer that is difficult to treat due to its resistance to both radiation and chemotherapy. This resistance is largely due to the unique biology of GBM cells, which can evade the effects of conventional treatments through mechanisms such as increased resistance to cell death and rapid regeneration of cancerous cells. Additionally, the blood–brain barrier makes it difficult for chemotherapy drugs to reach GBM cells, leading to reduced effectiveness. Despite these challenges, there are several treatment options available for GBM. The standard of care for newly diagnosed GBM patients involves surgical resection followed by concurrent chemoradiotherapy and adjuvant chemotherapy. Emerging treatments include immunotherapy, such as checkpoint inhibitors, and targeted therapies, such as bevacizumab, that attempt to attack specific vulnerabilities in GBM cells. Another promising approach is the use of tumor-treating fields, a type of electric field therapy that has been shown to slow the growth of GBM cells. Clinical trials are ongoing to evaluate the safety and efficacy of these and other innovative treatments for GBM, intending to improve with outcomes for patients.

1 December 2019 in Translational Research
Verified
Journal Article
Closed access
Md Abdus SubhanMd Abdus Subhan
Md Abdus Subhan
VTV.P. Torchilin
V.P. Torchilin

1 October 2020 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
Md Abdus SubhanMd Abdus Subhan
Md Abdus Subhan
VTVladimir P. Torchilin
Vladimir P. Torchilin

1 February 2015 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
Md Abdus SubhanMd Abdus Subhan
Md Abdus Subhan
TATanzir Ahmed
Tanzir Ahmed
NUNizam Uddin
Nizam Uddin
AAAbul Kalam Azad
Abul Kalam Azad
KBKulsuma Begum
Kulsuma Begum